Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Version of RECTIV® (nitroglycerin) ointment, 0.4%, with 180 days Competitive Generic Therapy (CGT) exclusivity
February 22, 2024 08:00 AM Eastern Daylight Time BRIDGEWATER,…
Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.
January 3, 2024 Only FDA-Approved As-Needed Treatment For The Approximately 6…
Cosette Pharmaceuticals Appoints Ted Smolenski as Vice President of Portfolio & Business Development
Experienced business development executive to accelerate Cosette’s growth…
Apurva Saraf, President and CEO of Cosette Pharmaceuticals, Honored with "CEO of the Year" Award by Avista Capital Partners
Apurva Saraf, President and CEO of Cosette Pharmaceuticals, Honored with…
Cosette Pharmaceuticals Partners With Mark Cuban Cost Plus Drug Company to Make CLOMID® More Affordable
Online Pharmacy to Offer Proven Fertility Medication at Low Cost BRIDGEWATER,…